Inimmune
蒙大拿 生技醫藥 - Montana Bioscience
Inimmune
資料下載：DM
Inimmune 為位於美國蒙大拿州之臨床階段生技公司，以發展次世代之疫苗和免疫治療為方向，團隊由具實力堅強、經驗豐富之合成和製程化學家、藥物劑型專家、和免疫學家所組成，公司之發展流程為以創新之治療方式解決先天免疫的所無法解決的問題，比如腫瘤、過敏性鼻炎、食物過敏和感染相關疫苗研發。
Inimmune (Missoula, MT) is a clinical stage biotechnology company located in Missoula, MT (USA) focused on developing the next generation of vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology. Our pipeline includes innovative new treatments to harness the innate immune system in areas of critical patient need such as oncology, allergic rhinitis, food allergy and infectious disease vaccines. Inimmune and ImmunAdd in Taipei, Taiwan have partnered to co-develop an improved synthetic “AS01 like” adjuvant. This Synthetic Adjuvant System (SAS) overcomes the challenges associated with resource limited and costly natural product production and isolation. SAS combines innovative and patented adjuvant technologies from Inimmune and ImmunAdd in a liposome based delivery system as a synthetic alternative to AS01.
Inimmune 和 ImmunAdd (優億、臺北臺灣)發展了優化的全合成類AS01佐劑系統，稱作合成佐劑系統（SAS），這系統具體解決天然物資源限制及成本高昂之生產困境。本技術乃⾃於Inimmune及ImmunAdd之創新的研究及專利的技術，所共同創造之合成替代之AS01微脂粒疫苗佐劑。
合成佐劑系統之效果： SAS 加上單珠流感抗原可引發具對多株流感病毒攻毒之保護力。
授權的機會：Inimmune 和 ImmunAdd 尋求授權 SAS 佐劑系統。
更多資訊請聯繫：Jay Evans, PhD jay.t.evans@inimmune.com 與 Pi-Hui Liang, PhD phliang@immunadd.com 。
Inimmune (Missoula, MT, USA) and ImmunAdd (Taipei City, Taiwan) have partnered to co-develop an improved synthec “AS01 like” adjuvant. This Synthec Adjuvant System (SAS) overcomes the challenges associated with resource limited and costly natural product producon and isolaon. SAS combines innovave and patented adjuvant technologies from Inimmune and ImmunAdd in a liposome based delivery system as a synthec alternave to AS01.
Synthec Adjuvant System: SAS + split-flu angen induces protecve immunity in a heterologous influenza challenge model.
Licensing Opportunities: Inimmune and ImmunAdd are seeking licensing partners for SAS.
For more information please contact: Jay Evans, PhD jay.t.evans@inimmune.com and Pi-Hui Liang, PhD phliang@immunadd.com
優億股份有限公司 ImmunAdd, Inc
優億股份有限公司(ImmunAdd Inc.)於 2022 年在台灣台北成立。本公司以化學合成自主發展佐劑產品為主要目標，並透過微脂體技術平台發展多種不同的佐劑系統，提供安全有效的疫苗佐劑組合解決方案。
Founded in 2022, ImmunAdd, Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation. We are developing next generation saponin adjuvants and using them as the basis for new combination adjuvants and adjuvanted vaccines. Our lead adjuvant, IA05, is a rationally designed analogue of the saponin adjuvant QS-21. IA05 elicits immune responses comparable to or better than QS-21 and is better tolerated and more stable. With IA05 as the foundation, ImmunAdd is designing adjuvant platforms able to deliver a specific immune response .
電話：04-26313368
E-mail：phliang@immunadd.com
地址：8F.-6, No. 57, Fuxing N. Rd., Songshan Dist., Taipei City 10595, Taiwan